WASHINGTON, DC (January 7th, 2026) – Today, the Biotechnology Innovation Organization (BIO) announced the launch of the BIO Investment Council (BIC). The newly established council aims to serve small and emerging biotech innovators by increasing engagement between investors and BIO members to accelerate capital formation, drive innovation, and enable greater M&A activity across the biotechnology sector.BIO Board Member, Doug Dieter, Dr.P.H., Partner at Ares Management and Co-Head of Ares Specialty Healthcare, will chair the BIC. Dr. Nessan Bermingham, Operating Partner at Khosla Ventures, will serve as Vice Chair.“Private capital funding is the lifeblood of America’s small to midsize biotech innovators,” said John F. Crowley, President and CEO of BIO. “Today, more than half of innovative new medicines originate in small to mid-size biotech companies. Yet, despite incredible scientific progress and promise, significant challenges remain in private capital formation to support emerging companies. The launch of the BIO Investment Council, under the leadership of Doug and Ness, affirms our commitment as we seek to ensure biotech start-ups have the capital needed to innovate, grow, and ultimately deliver ground-breaking treatments that have enabled the US biotech to lead the world and improve the lives of millions of patients.”While overall VC funding into biopharmaceutical companies has remained stable, for the first time in a decade, investments in clinical-stage companies surpassed those in preclinical-stage companies. This discrepancy underscores the urgent need to better align small and emerging biotech companies with the right investors in the earliest stages of their research.“I am honored to take the helm of BIC at a time when urgent leadership is needed to secure U.S. advancement in biotechnology. Small and emerging biotech companies are facing unprecedented challenges, and through BIC, our goal is to remove barriers to accessing capital and improve the…

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO)  released the following statement on changes announced to the US childhood vaccine schedule.“American health is as unique as America itself. The US vaccination schedule is the result of decades of a rigorous, public-facing, science-based process. The US schedule considers US epidemiology, our healthcare system strengths and challenges, and the economic impact of infectious diseases on the American people.“Today, that America first gold standard was upended with a wholesale change to the schedule without any clear medical or scientific reason.“Weakening recommendations for vaccines in the name of ideology over epidemiology undermines America’s leadership in public health and trust in our health authorities. It stokes fear and confusion among parents and health care providers. Most importantly, instead of making America healthy again, these actions increase the risk of serious illness for all Americans, especially children. Enough is enough. We must return to decisions guided by medical expertise and scientific evidence.”###About the Biotechnology Innovation Organization (BIO)BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe. BIO members range from biotech start-ups to some of the world’s largest biopharmaceutical companies – all united by the same goal: to develop medical and scientific breakthroughs that prevent and fight disease, restore health, and improve patients’ lives. BIO also organizes the BIO International Convention and a series of annual conferences that drive partnerships, investment, and progress within the sector. Learn more at bio.org.